

PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

Julia M. Kim, Sandra Y. Lin, Catalina Suarez-Cuervo, Yohalakshmi Chelladurai,
Murugappan Ramanathan, Jodi B. Segal and Nkiruka Erekosima
Pediatrics; originally published online May 6, 2013;
DOI: 10.1542/peds.2013-0343

The online version of this article, along with updated information and services, is
located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/early/2013/04/30/peds.2013-0343>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2013 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

AUTHORS: Julia M. Kim, MD, MPH,^a Sandra Y. Lin, MD,^b Catalina Suarez-Cuervo, MD,^c Yohalakshmi Chelladurai, MBBS, MPH,^c Murugappan Ramanathan, MD,^b Jodi B. Segal, MD, MPH,^c and Nkiruka Erekosima, MD, MPH^d

Departments of ^aPediatrics, Division of General Pediatrics and Adolescent Medicine, ^bOtolaryngology-Head and Neck Surgery, ^cMedicine, Division of General Internal Medicine, and ^dMedicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland

KEY WORDS

allergen-specific immunotherapy, asthma, pediatric, rhinitis, rhinoconjunctivitis, subcutaneous immunotherapy, sublingual immunotherapy, systematic review

ABBREVIATIONS

AHRQ—Agency for Healthcare Research and Quality

QoL—quality of life

RCTs—randomized controlled trials

SCIT—subcutaneous immunotherapy

SIT—allergen-specific immunotherapy

SLIT—sublingual immunotherapy

Dr Kim selected articles for inclusion, extracted data, graded the strength of the evidence, and drafted and revised the manuscript; Dr Lin selected articles for inclusion, extracted data, graded the strength of the evidence, and reviewed and revised the manuscript; Dr Suarez-Cuervo designed the data abstraction forms, coordinated data abstraction and data management, selected articles for inclusion, extracted data, and reviewed the manuscript; Drs Chelladurai and Ramanathan selected articles for inclusion, extracted data, graded the strength of the evidence, and reviewed the manuscript; Dr Segal supervised all steps of the systematic review process (including conceptualization and design), and critically reviewed and revised the manuscript; Dr Erekosima selected articles for inclusion, extracted data, graded the strength of the evidence, and critically reviewed and revised the manuscript; and all authors approved the final manuscript as submitted.

www.pediatrics.org/cgi/doi/10.1542/peds.2013-0343

doi:10.1542/peds.2013-0343

Accepted for publication Feb 21, 2013

Address correspondence to Julia M. Kim, MD, MPH, Johns Hopkins University School of Medicine, Department of Pediatrics, Division of General Pediatrics and Adolescent Medicine, David Rubenstein Child Health Building, 200 N Wolfe St, Room 2088, Baltimore, MD 21287. E-mail: jkim315@jhmi.edu

(Continued on last page)

abstract



BACKGROUND AND OBJECTIVE: Subcutaneous immunotherapy (SCIT) is approved in the United States for the treatment of pediatric asthma and rhinitis; sublingual immunotherapy (SLIT) does not have regulatory approval but is used in clinical practice. The objective of this study was to systematically review the evidence regarding the efficacy and safety of SCIT and SLIT for the treatment of pediatric asthma and allergic rhinoconjunctivitis.

METHODS: Two independent reviewers selected articles for inclusion, extracted data, and graded the strength of evidence for each clinical outcome. All studies were randomized controlled trials of children with allergic asthma or rhinoconjunctivitis treated with SCIT or an aqueous formulation of SLIT. Data sources were Medline, Embase, LILACS, CENTRAL, and the Cochrane Central Register of Controlled Trials through May 2012.

RESULTS: In 13 trials, 920 children received SCIT or usual care; in 18 studies, 1583 children received SLIT or usual care. Three studies compared SCIT with SLIT head-to-head in 135 children. The strength of evidence is moderate that SCIT improves asthma and rhinitis symptoms and low that SCIT improves conjunctivitis symptoms and asthma medication scores. Strength of evidence is high that SLIT improves asthma symptoms and moderate that SLIT improves rhinitis and conjunctivitis symptoms and decreases medication usage. The evidence is low to support SCIT over SLIT for improving asthma or rhinitis symptoms or medication usage. Local reactions were frequent with SCIT and SLIT. There was 1 report of anaphylaxis with SCIT.

CONCLUSIONS: Evidence supports the efficacy of both SCIT and SLIT for the treatment of asthma and rhinitis in children. *Pediatrics* 2013;131:1–13

Asthma is one of the most common chronic diseases of childhood, affecting >6 million children in the United States.¹ Allergic rhinitis affects up to 40% of children in the United States.² Allergen-specific immunotherapy (SIT) is frequently used to treat asthma and allergic rhinitis and may modify the course of the disease. SIT is typically recommended for children whose asthma and allergic rhinitis symptoms cannot be adequately controlled with medication or environmental changes.

The US Food and Drug Administration has approved the use of allergen extracts for subcutaneous immunotherapy (SCIT) to treat allergic rhinitis and allergic asthma. Considerable interest has developed in using sublingual immunotherapy (SLIT), which is currently prescribed off-label in the United States. SLIT involves placement of the allergen under the tongue for local absorption, to desensitize the allergic individual over a period of months to years; this method has gained favor in Europe,³ where sublingual tablets and aqueous immunotherapy have been approved.

The objective of the current systematic review was to summarize the evidence regarding the efficacy and safety of SCIT and SLIT for the treatment of pediatric asthma and allergic rhinoconjunctivitis. This review evaluated only the SCIT allergen formulations that are currently available in the United States or SLIT formulations with similar off-label substitutes. This report is derived from a comparative effectiveness review evaluating SIT in adult and pediatric populations commissioned by the US Agency for Healthcare Research and Quality (AHRQ).

METHODS

Technical experts were recruited for input on the research questions and search strategy. We developed a protocol for this review and posted it online, following guidelines for systematic

review (http://effectivehealthcare.ahrq.gov/ehc/products/270/665/SIT_Protocol_20110824.pdf). Additional details on the methods appear in the full AHRQ Evidence Report, Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma, Comparative Effectiveness Review (<http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=665>).

Data Sources and Selection

We searched Medline, Embase, LILACS, CENTRAL, and the Cochrane Central Register of Controlled Trials, from inception through May 21, 2012 (Supplemental Appendix Fig 1). Two investigators independently reviewed titles, abstracts, and full articles for possible inclusion. Disagreements were resolved by consensus. We included randomized controlled trials (RCTs), exclusively studying children with allergic asthma and/or rhinoconjunctivitis due to inhaled allergens, with diagnoses confirmed by using objective testing (positive result on skin allergy testing and/or in vitro specific immunoglobulin E allergy testing) (Supplemental Appendix Table 1). We included only studies evaluating SCIT formulations available in the United States or SLIT formulations with close off-label substitutes, alone or in combination with usual care, and compared them with placebo, pharmacotherapy, or other SIT regimens. Studies of sublingual tablets were not included because this formulation is currently not available for clinical use in the United States. We included only trials that clearly reported allergen dosages, evaluated clinical outcomes or safety, and were published in English.

Data Extraction and Quality Assessment

One investigator extracted data into standardized forms, and accuracy was

confirmed by a second reviewer. We used DistillerSR for data management (Evidence Partners, Ottawa, Ontario, Canada). Data from the final time point were reported. For outcomes with multiple measurements during a single season, data collected at peak allergen season were used.

The quality of each study was assessed by using a modified Cochrane Collaboration Tool for Assessing Risk of Bias to record the adequacy of randomization, allocation concealment, blinding, completeness of data reporting, sponsor company involvement, and other sources of potential bias.⁴ Two independent reviewers assigned ratings of low, medium, or high risk of bias based on this assessment. Disagreements were resolved by consensus.

Data Synthesis and Analysis

Data were stratified according to outcome, intervention, and allergen, and synthesized qualitatively. We graded the quantity, quality, and consistency of the evidence by adapting an evidence-grading scheme recommended by the Guide for Conducting Comparative Effectiveness Reviews.⁵ The magnitude of effect was classified according to the percent difference in pre-to-post change comparing the SIT group and comparator group: <15% was defined as a weak difference; a 15% to 40% difference was defined as moderate; and >40% was defined as a strong effect (Supplemental Appendix Table 2). The body of evidence for each primary outcome was graded as high, moderate, low, or insufficient (Supplemental Appendix Table 3). The evidence grade reflects the likelihood that additional research will change the conclusions about the intervention. Adverse events were categorized as local or systemic. Only studies that observed adverse events were included in the safety evaluation.

RESULTS

Our search generated 7746 citations (Fig 1). We included 34 articles relevant to children: 13 trials of SCIT, 18 trials of SLIT, and 3 trials comparing SCIT with SLIT. The findings are summarized according to intervention and outcomes (Table 1). We describe asthma findings only for studies that confirmed asthma diagnoses by using objective measures or previously established guidelines. Five of the included studies were not graded because all study arms received immunotherapy.^{6–10}

Study and Population Characteristics for SCIT

Thirteen studies including 920 children aged 3 to 18 years evaluated SCIT for clinical outcomes. The primary diagnosis was asthma in 7 studies,^{6,7,11–15} rhinoconjunctivitis in 1 study,¹⁶ and asthma with rhinitis/rhinoconjunctivitis in 5 studies.^{8,9,17–19} The majority of studies used a single allergen for SCIT. Dust mites were evaluated in 8 of the 13 studies. All studies allowed either routine medications or rescue medications. The maintenance dosing interval varied

from biweekly dosing to dosing every 6 weeks, and the duration of treatment ranged from 4 months to 3 years. There was great heterogeneity in the allergen dose delivered and the reporting of dosage units.

Clinical Outcomes of SCIT in Children

Asthma

Six RCTs with 550 subjects evaluated SCIT for control of asthma symptoms relative to placebo^{11,15,18,19} or pharmacotherapy^{13,17} (Table 1; Supplemental Appendix Table 4). Four studies evaluated a single allergen^{11,13,18,19} and 2 used multiple allergens.^{15,17} Single-allergen SCIT studies demonstrated improvement in asthma symptoms, compared with placebo or pharmacotherapy, with moderate to strong magnitudes of effect. In contrast, 1 study with a low risk of bias enrolled 121 children with moderate to severe asthma already receiving appropriate asthma medications and found no improvement, compared with placebo, with SCIT using multiple allergens.¹⁵ The overall strength of evidence is moderate that SCIT using a single allergen improves asthma symptoms relative to placebo or pharmacotherapy. However, there is low-grade evidence that SCIT using multiple allergens does not improve asthma symptoms in subjects with moderate to severe asthmatics.

Four studies with 470 participants evaluated SCIT for improvement of asthma medication usage (Supplemental Appendix Table 5),^{11,13,15,17} and 2 studies with 80 participants evaluated combined asthma and rhinitis/rhinoconjunctivitis medication usage (Supplemental Appendix Table 6).^{18,19} Four single-allergen studies demonstrated greater reduction in medication usage for asthma with or without rhinoconjunctivitis in the SCIT group than in the comparator.^{11,13,18,19} One study with 121 participants and




FIGURE 1

Flow diagram of evidence search and selection. ^aThe total number of articles excluded may be exceeded by the number of reasons for exclusion, because articles were excluded by 2 reviewers at this level.

^bOther reasons: control group is healthy population, routes of administration not included (eg, oral, nasal, lymph node), abandoned interventions, outcomes not reported, no comparator group, continued medical education reports, editorials or reviews, studies about mechanism of action, other allergies (food, aspirin), study in animals or in vitro, or ≤ 6 patients per arm.

TABLE 1 Clinical Outcomes Summary for SCIT and SLIT in Children

Outcome	No. of Studies	No. of Participants	Allergens (n Studies)	Comparators (n Studies)	Summary of Findings	Strength of Evidence
SCIT studies						
Asthma symptoms	6	550	Dust mite (1) <i>Cladosporium</i> (1) Rye (1) <i>Alternaria</i> (1) Multiple (2)	SCIT (2) vs placebo (4) vs pharmacotherapy (2)	The SCIT group showed greater improvement than the comparison group in 5 of 6 studies	Moderate that SCIT improves asthma symptoms more than comparators
Asthma medication scores	4	470	Dust mite (1) Rye (1) Multiple (2)	SCIT vs placebo (2) vs pharmacotherapy (2)	2 studies showed significant reduction in medication consumption with SCIT compared with usual care; 1 study found no difference between groups, 1 study did not report results from direct comparison between groups	Low that SCIT improves asthma medication scores more than comparators
Asthma plus rhinitis/rhinoconjunctivitis medication scores	2	80	<i>Cladosporium</i> (1) <i>Alternaria</i> (1)	SCIT vs placebo (2)	Both studies showed reduction in asthma and rhinoconjunctivitis medication consumption in the SCIT group	Low that SCIT improves asthma plus rhinitis/rhinoconjunctivitis medication scores more than comparators
Combined symptom-medication scores	2	85	Dust mite (1) <i>Alternaria</i> (1)	SCIT vs placebo (1) vs SCIT (1) (high- vs low-dose vs placebo)	Both studies showed significant improvement in the SCIT group compared with placebo	Low that SCIT improves asthma or asthma plus rhinoconjunctivitis combined symptom-medication scores more than comparators
Rhinitis/rhinoconjunctivitis symptoms	3	285	<i>Alternaria</i> (1) <i>Cladosporium</i> (1) Birch (1)	SCIT vs placebo (3)	2 studies showed statistically significant improvement in symptoms with SCIT; 1 study found no significant improvement with SCIT	Moderate that SCIT improves rhinitis/rhinoconjunctivitis symptoms more than comparators
Conjunctivitis symptoms	3	285	<i>Alternaria</i> (1) <i>Cladosporium</i> (1) Birch (1)	SCIT vs placebo (3)	2 studies reported significant improvement in symptoms with SCIT; 1 study found no significant improvement with SCIT	Low that SCIT improves conjunctivitis symptoms more than comparators
Rhinoconjunctivitis QoL	2	350	<i>Alternaria</i> (1) Multiple (1)	SCIT vs placebo (1) vs pharmacotherapy (1)	Both studies reported significant improvement in disease-specific QoL in the SCIT arm	Low that SCIT improves rhinoconjunctivitis quality of life more than comparators
SLIT studies						
Asthma symptoms	9	471	Dust mite (7) Tree mix (1) <i>Parietaria</i> (1)	SLIT vs placebo (8) vs SLIT (1) (high versus low dose versus placebo)	All 9 studies demonstrated improvement in the SLIT group. Higher dose of SLIT showed greater improvement compared with lower dose/placebo. There was a strong magnitude of effect in 6 studies.	High that SLIT improves asthma symptoms more than comparators
Rhinitis or rhinoconjunctivitis symptoms	12	1065	Grass mix (2) Dust mite (6) <i>Parietaria</i> (2) Olive (1)	SLIT vs placebo (10) vs control (1) vs SLIT (1) (high- vs low-dose vs placebo)	11 studies showed greater improvement in symptoms with SLIT. One placebo controlled study found no improvement in symptoms.	Moderate that SLIT improves rhinitis or rhinoconjunctivitis symptoms more than comparators
Asthma plus rhinitis or rhinoconjunctivitis symptoms	1	98	Tree mix (1) Tree mix (1)	SLIT (high-dose) vs SLIT (low-dose) vs placebo	This study demonstrated improvement in the SLIT group, with higher dose showing greater improvement	Moderate that SLIT improves asthma plus rhinitis or rhinoconjunctivitis symptoms more than comparators

TABLE 1 Continued

Outcome	No. of Studies	No. of Participants	Allergens (n Studies)	Comparators (n Studies)	Summary of Findings	Strength of Evidence
Conjunctivitis symptoms	5	513	Dust mite (2) Olive (1) Tree mix (1) <i>Parietaria</i> (1)	SLIT vs placebo vs placebo (4) vs SLIT (1) (high- vs low-dose vs placebo) SLIT	4 studies showed greater improvement in symptoms in the SLIT group compared with placebo. Higher dose showed greater improvement. The direction of change could not be determined in one study.	Moderate that SLIT improves conjunctivitis symptoms more than comparators
Medication use	13	1078	Dust mite (6) <i>Parietaria</i> (2) Olive (1) Tree mix (1) Multiple (1) Grass mix (1) Dust mite mix (1) Dust mite (1) Grass mix (1)	vs placebo (11) vs control (1) vs SLIT (1) (high- vs low-dose versus placebo) SLIT vs control (2) SLIT vs placebo (2)	11 studies showed a reduction in medication use in the SLIT group; 1 study showed no difference between SLIT and placebo. The direction of change could not be determined in one study. There was a moderate or strong magnitude of effect in 6 studies.	Moderate that SLIT improves medication use more than comparators
Combined medication plus symptoms	2	329	Grass mix (1) Dust mite mix (1)	SLIT vs control (2)	1 study showed greater improvement in the SLIT group; 1 study showed no difference	Low that SLIT improves combined medication plus symptoms scores more than comparators
Rhinoconjunctivitis QoL	2	461	Dust mite (1) Grass mix (1)	SLIT vs placebo (2)	1 study showed no improvement in disease-specific QoL; 1 study showed no difference between SLIT and placebo	Insufficient that SLIT improves disease-specific QoL more than comparators
SCIT vs SLIT studies						
Asthma symptoms	3	135	Dust mite (3)	SCIT vs SLIT; 1 placebo-controlled, 2 pharmacotherapy-controlled	1 study favored SLIT; 1 study favored SCIT; 1 study weakly favored SCIT, because SCIT, SLIT, and SCIT plus SLIT all showed significant reduction in symptoms	Low favoring SCIT over SLIT for improving asthma symptoms
Rhinitis or rhinoconjunctivitis symptoms	3	135	Dust mite (3)	SCIT vs SLIT; 1 placebo-controlled, 2 pharmacotherapy-controlled	3 studies favored SCIT	Low favoring SCIT over SLIT for improving rhinitis or rhinoconjunctivitis symptoms
Medication scores	3	135	Dust mite (3)	SCIT vs SLIT; 1 placebo-controlled, 2 pharmacotherapy-controlled	2 studies favored SCIT for rhinitis medication use reduction, 1 study favored SLIT for total medication score reduction	Low favoring SCIT over SLIT for decreasing medication use

low risk of bias showed similar reductions in asthma medication use in both the SCIT and placebo groups.¹⁵ The strength of evidence is low that SCIT improves medication use for asthma or combined asthma and rhinoconjunctivitis.

Two studies with 85 participants evaluated SCIT for improvement on a combined symptom and medication score (Table 1; Supplemental Appendix Table 7).^{12,19} Both studies showed greater improvement in the SCIT group compared with placebo. The strength of evidence is low that SCIT improves combined symptom and medication scores.

Rhinitis

Three placebo-controlled trials with 285 subjects evaluated SCIT for control of rhinitis and rhinoconjunctivitis symptoms (Table 1; Supplemental Appendix Table 8).^{16,18,19} These included single- and multiple-allergen regimens. Two studies allowed conventional therapy,^{16,18} and 1 study allowed only rescue therapy in the treatment arms.¹⁹ The largest study, with 205 participants and a medium risk of bias, strongly favored SCIT with grass/birch mix along with conventional therapy over placebo.¹⁶ The second study, with 50 participants and medium risk of bias, moderately favored SCIT over placebo.¹⁹ The smallest study, with 30 participants and a low risk of bias, weakly favored SCIT over placebo.¹⁸ Overall, we found moderate-strength evidence that SCIT controls rhinitis and rhinoconjunctivitis symptoms in children better than placebo.

Conjunctivitis

Three placebo-controlled trials with 285 participants evaluated SCIT, compared with placebo, for control of conjunctivitis symptoms (Table 1; Supplemental Appendix Table 9).^{16,18,19} Risk of bias was low to medium. One study with

a medium risk of bias and 205 participants reported significant improvement in conjunctivitis symptom scores, although actual scores were not reported.^{16,19} Kuna et al¹⁹ also found significant improvement in symptoms, with strong magnitude of effect, after 3 years of SCIT. The third study, with 30 participants and low risk of bias, revealed no significant improvement in conjunctivitis symptoms.¹⁸ The strength of evidence is low that SCIT improves conjunctivitis symptoms.

Other Outcomes

Quality of life (QoL) was evaluated in 2 studies (Table 1; Supplemental Appendix Table 10).^{17,19} One study with 50 participants and medium risk of bias demonstrated a significant improvement in QoL scores after 3 years of SCIT in children and adolescents with asthma and rhinitis, as well as in the parents of children receiving SCIT.¹⁹ Another study with 300 participants and a high risk of bias reported no significant difference in QoL with SCIT compared with placebo.¹⁷

Prevention of asthma was evaluated in 1 study. Möller et al¹⁶ investigated asthma prevention as a primary outcome and observed, among 151 children with allergic rhinoconjunctivitis without asthma, a 2.5-fold greater odds of preventing new onset of asthma after 3 years of SCIT versus placebo. Benefit persisted after 5 years and after 10 years.^{20,21}

Safety of SCIT in Children

Adverse events were observed in 10 of the 13 studies.^{6–8,12,14,17–19} Local reactions (injection site redness and swelling) were common in both the SCIT and placebo arms, occurring in up to 54% of SCIT and 53% of placebo injections in 1 study (Table 2).⁷ Systemic reactions included respiratory reactions such as mild to severe bronchospasm in 1% to 30% of patients

or up to 4.6% of injections; unspecified or general systemic reactions in 3% to 34% of patients; and urticaria in 2% to 19% of patients. There were no reports of anaphylaxis or death.

Study and Population Characteristics for SLIT

Eighteen studies that enrolled 1583 children aged 4 to 18 years evaluated SLIT for clinical outcomes.^{10,22–38} The primary diagnoses included asthma,^{22–24} rhinitis/rhinoconjunctivitis,^{25–30} and asthma with rhinitis/rhinoconjunctivitis.^{10,31–38} Immunotherapy targeted predominantly dust mite^{22–26,32–34,38} and grass.^{10,28–30} The majority of the studies (60%) used multiple allergens. Most of the comparator group(s) received placebo drops (15 studies), other SLIT regimens (3 studies), or conventional treatment or symptomatic therapy (2 studies). Studies allowed either conventional treatment (12 studies) or only rescue allergy medications (6 studies) in the SLIT arm. The maintenance dosing interval varied from daily to twice weekly, and treatment duration ranged from 6 months to 3 years.

Clinical Outcomes of SLIT in Children

Asthma

Nine studies including 471 participants evaluated SLIT for control of asthma symptoms (Table 1; Supplemental Appendix Tables 11 and 12).^{22–24,32–35,37,38} Seven studies evaluated dust mite allergen.^{22–24,32–34,38} The SLIT-treated children in the placebo-controlled studies demonstrated moderate to strong improvement in asthma symptoms. The risk of bias was low in 3 studies.^{22,32,34} Therefore, the strength of evidence is high that SLIT improves asthma symptoms, compared with placebo.

Rhinitis

Twelve trials including 1065 children evaluated SLIT for control of rhinitis or

TABLE 2 Adverse Event Outcomes Summary for SCIT and SLIT Studies in Children

Type of Reaction	Allergen (n studies)	AEs	No. of AEs or Affected Patients/Total No. of Patients in Study Arms Reporting AEs		Range of AEs		Severity	
			Treatment Arm	Comparator Arm	Treatment Arm	Comparator Arm	Treatment Arm	Comparator Arm
SCIT studies ^a								
Local reactions (patients), 4 studies	Dust mite (3) <i>Alternaria</i> (1)	Local swelling or edema	SCIT	Placebo	SCIT	Placebo	SCIT	Placebo
			13/82 patients	NR	11%–17%	NR	Unspecified (23%) Mild (44%) Moderate (33%)	NR
Local reactions (events), 3 studies	Dust mite (1) <i>Cladosporium</i> (1) Dog (1)	Redness or swelling	578 events/61 patients	251 events/12 patients (1 study reported AEs in control arm)	53%–54% of injections (0.25–20 events/patient)	Percentage or range not quantifiable	Mild (100%)	Mild (100%)
			1 study: 265 events/ 492 injections (46 patients)			1 study: (21 events/patient)		
Cutaneous reactions (patients), 2 studies	Dust mite (1)	Urticaria	6/167 patients	NR	2%–19%	NR	Unspecified (100%)	NR
Respiratory reactions (patients), 3 studies	Gladosporium (1) Dust mite (2) Multiple (1)	Bronchospasm Wheezing	10/203 patients	NR	1%–30%	NR	Unspecified (14%) Severe (86%)	NR
			19 events/30 patients, 492 injections	NR	3.5%–4.6% of injections	NR	Mild (96%)	NR
Respiratory reactions (events), 1 study	Dust mite (1)	Cough Dyspnea Bronchial asthma			0.7–0.8 events/patient 3%–34%	7%–10%	Moderate (4%) Unspecified Mild	Unspecified
Systemic reactions:								
General symptoms (patients), 2 studies	Multiple (1) <i>Alternaria</i> (1)	Systemic reactions Headache, mild flushing, and redness	22/91 patients	6/80 patients				
Unspecified reactions (patients), 1 study	Multiple (1)	Unspecified	5/15 patients	NR	33%	NR	Mild (100%)	NR
Unspecified reactions (events), 1 study	<i>Cladosporium</i> (1)	Unspecified systemic reactions	45 events/16 patients in 1 study that did not report number of injections	NR	2.8 events/ patient	NR	Unspecified (100%)	NR
SLIT studies ^b								
Local reactions (patients), 12 studies	Grass mix (4) Dust mite (4) Tree (2) Parietaria (2)	Oral, labial, pharyngeal, itching (buccal, sublingual), swelling, irritation, reddening, tingling	SLIT	Placebo	SLIT	Placebo	SLIT	Placebo
			131/712 patients	52/342 patients (7 studies reported AEs in control arm)	0.2%–50%	6%–25%	Unspecified (86%) Mild (14%)	Unspecified (94%) Mild (6%)
Upper respiratory reactions (patients), 5 studies	Dust mite (2) Trees (1) <i>Parietaria</i> (1) Grass mix (1)	Nasal symptoms, rhinitis	214/348 patients	196/275 patients (4 studies reported AEs in control arm)	3%–92%	3%–94%	Unspecified (94%) Severe (4%)	Unspecified (100%)

TABLE 2 Continued

Type of Reaction	Allergen (n studies)	AEs	No. of AEs or Affected Patients/Total No. of Patients in Study Arms Reporting AEs		Range of AEs		Severity	
			Treatment Arm	Comparator Arm	Treatment Arm	Comparator Arm	Treatment Arm	Comparator Arm
Lower respiratory reactions (patients), 5 studies	Dust mite (2) Grass mix (2) <i>Parietaria</i> (1)	Asthma Shortness of breath Cough	125/429 patients	117/243 patients (3 studies reported AEs in control arm, 1 study had AE only in control arm)	0%–67%	10%–69%	Unspecified (92%) Mild (6%) Severe (2%)	Unspecified (98%) Mild (1%) Severe (1%)
Cutaneous reactions (patients), 5 studies	Dust mite (2) Grass mix (2) Multiple (1)	Urticaria Rash Eczema Itch	118/461 patients	117/281 patients (3 studies reported AEs in control arm)	0.7%–57%	2%–65%	Unspecified (98%) Mild (2%)	Unspecified (99%) Mild (1%)
GI reactions (patients), 8 studies	Dust mite (3) Grass mix (2) Trees (1) <i>Parietaria</i> (1) Multiple (1)	Abdominal pain Abdominal swelling Diarrhea Gastrointestinal complaints	186/548 patients	153/243 patients (3 studies reported AEs in control arm)	0.7%–74%	33%–73%	Unspecified (83%) Mild (0.5%)	Unspecified (100%)
Ocular reactions (patients), 7 studies	Dust mite (2) Grass mix (1) Trees (1) <i>Parietaria</i> (1)	Conjunctivitis, eye symptoms	130/317 patients	137/243 patients (3 studies reported AEs in control arm)	3%–55%	5%–65%	Unspecified (94%) Mild (1%) Severe (5%)	Unspecified (100%)
General symptoms (patients), 9 studies	Dust mite (6) Grass mix (1) Trees (1) <i>Parietaria</i> (1)	Tiredness Flushing, allergic reaction, headaches Allergy	120/393 patients	103/282 patients (5 studies reported AEs in control arm)	7%–63%	8%–67%	Unspecified (81%) Mild (19%)	Unspecified (91%) Mild (9%)
SCIT vs SLIT studies ^c			SCIT/SLIT	Placebo	SCIT/SLIT	Placebo	SCIT/SLIT	Placebo
Local reactions (patients), 1 study SLIT	Dust mite (1)	Oral pharyngeal itching, mild edema	SLIT: 3/10 patients	Placebo: 2/10 patients	30%	20%	Unspecified (100%)	Unspecified (100%)
Local reactions (patients), 2 studies SCIT	Dust mite (2)	Injection site reaction	SCIT: 3/26 patients	Placebo: 2/10 patients	12% (6%–20%)	20%	Mild (100%)	Unspecified (100%)
Respiratory reactions (patients), 2 studies SCIT	Dust mite (2)	Asthma, dyspnea, wheezing	SCIT: 3/26 patients	NR	12% (6%–18%)	NR	Moderate (67%) Severe (33%)	NR
Anaphylaxis (patients), 1 study SCIT	Dust mite (1)	Flushing, wheezing, dyspnea requiring adrenaline	SCIT: 1/16 patients	NR	6%	NR	Severe	NR

AEs, adverse events; NR, no AEs reported.

^a None of the SCIT studies reported gastrointestinal (GI), general symptoms, or anaphylactic reactions.^b None of the SLIT studies reported cardiovascular or anaphylactic reactions.^c None of the SCIT versus SLIT studies reported upper respiratory, cutaneous, GI, cardiovascular, ocular, or general symptoms.

rhinoconjunctivitis symptoms (Table 1; Supplemental Appendix Table 13).^{25–29,32–38} One-half of the studies evaluated dust mite allergens.^{25,26,32–34,38} Risk of bias was low in 4 studies,^{27,29,32,34} medium in 6 studies,^{26,33,35–38} and high in 2 studies.^{25,28} Five studies demonstrated significant improvement in rhinitis/rhinoconjunctivitis scores with SLIT, compared with placebo, with moderate to strong magnitudes of effect.^{33,34,36–38} Four studies did not show significant improvement with SLIT,^{25,26,29,32} and 1 of these favored placebo.²⁶ The strength of evidence is moderate that SLIT improves rhinitis symptoms.

Conjunctivitis

Five RCTs including 513 participants evaluated SLIT for control of conjunctivitis symptoms (Table 1; Supplemental Appendix Table 14).^{25,34–37} Two placebo-controlled trials of olive and tree mix allergens with medium risk of bias that enrolled 70 and 98 children, respectively, demonstrated moderate to strong magnitude of effect for SLIT.^{36,37} One study of dust mite immunotherapy in 58 children, with a low risk of bias and weak magnitude of effect, showed little improvement with SLIT compared with placebo.³⁴ One study of dust mite allergen with 257 children and a high risk of bias and another study of *Parietaria* allergen with 30 children and a low risk of bias reported improvement with SLIT, although we could not determine the magnitude of effect.^{25,35} The strength of evidence is moderate that SLIT improves conjunctivitis symptoms.

Medication Scores

Medication scores were reported in 13 studies with 1078 participants (Table 1; Supplemental Appendix Table 15).^{22–29,32,33,35–37} Six studies evaluated dust mite allergen.^{22–26,32} The placebo-controlled studies demonstrated significant reductions in medication

use in the SLIT group relative to the placebo group, with moderate to strong magnitudes of effect in patients with asthma and/or rhinitis. The magnitudes of effect could not be determined in 7 studies.^{25,27–29,32,35,36} The risk of bias across these studies was mixed. The strength of evidence is moderate that SLIT decreases medication use.

Other Outcomes

Combined symptom plus medication scores were reported in 2 SLIT trials with 329 participants (Table 1; Supplemental Appendix Table 16).^{28,31} Symptom scores included nasal, eye, and bronchial symptoms. One study of 216 participants with asthma and rhinitis and a medium risk of bias showed a strong effect, with lower scores on the symptom and medication use measure with SLIT than with conventional care.³¹ One study of grass mix allergen that included 113 children with rhinoconjunctivitis and had a high risk of bias reported no significant difference between SLIT and conventional therapy, although the magnitude of effect could not be determined.²⁸ The strength of evidence is low that SLIT decreases the combination of symptoms and medication use for asthma and rhinitis.

QoL was reported in 2 studies involving 461 participants; QoL was measured by using the Pediatric and Adolescent Rhinoconjunctivitis Quality of Life questionnaires (Table 1; Supplemental Appendix Table 17).^{25,29} One study reported no improvement in QoL,²⁹ and another reported no difference between the SLIT and placebo groups after 2 years.²⁵ There is insufficient evidence to evaluate the impact of SLIT on disease-specific QoL.

Disease modification was addressed in 3 studies.^{24,27,31} Niu et al²⁴ found significantly more patients with improved asthma classification from mild/moderate

persistent asthma to mild intermittent asthma after 6 months of SLIT with dust mite allergen, compared with placebo. Marogna et al³¹ found no significant difference in the percentage of children with mild intermittent asthma after 3 years of SLIT, compared with placebo. La Rosa et al²⁷ also found no difference in rhinitis symptoms during *Parietaria* pollen season after 8 years of follow-up in the SLIT and placebo groups.

Prevention of asthma was addressed in 3 studies.^{27,28,31} Novembre et al²⁸ found that children receiving conventional therapy had a 3.8-fold increased risk of developing asthma compared with those receiving SLIT for 3 years. Marogna et al³¹ found a lower occurrence of new mild, persistent asthma in patients receiving SLIT compared with a conventional-therapy group after 3 years. La Rosa et al²⁷ found no difference, after treatment for 2 years, in the number of patients with asthma in the SLIT versus placebo groups at 8 years of follow-up.

Two studies addressed the development of new sensitivities.^{27,31} Marogna et al³¹ found a 40% decreased odds of developing new sensitivities after 3 years of SLIT, compared with pharmacotherapy. La Rosa et al²⁷ found no difference in the number of new sensitizations in monosensitized children treated with SLIT, compared with placebo, after 8 years of follow-up.

Safety of SLIT in Children

Local reactions, such as oral itching and swelling, were common but mild (Table 2). Twelve studies reported local reactions in 0.2% to 50% of patients receiving SLIT and 6% to 25% of patients receiving placebo.^{22,25,27–31,35–37}

Systemic reactions were commonly reported in both the SLIT and placebo groups, but no life-threatening reactions, anaphylaxis, or deaths were reported in these trials. From most commonly

to least commonly reported, the symptoms or reactions were characterized as general, gastrointestinal, ocular, respiratory, and cutaneous. Although severe systemic reactions were rare, 1 study reported severe rhinitis and severe asthma symptoms in children who exceeded their maximum dose.³⁴ These adverse events resolved when the children returned to a lower dose.

Study and Population Characteristics: SCIT Versus SLIT

Three RCTs of dust mite immunotherapy reported on the efficacy and safety of SCIT, compared head-to-head with SLIT in children.^{39–41} These 3 studies included 135 children, 5 to 14 years of age, with a primary diagnosis of asthma with rhinitis. One study allowed the use of conventional medications,³⁹ and 2 studies allowed only rescue medications.^{40,41} The maintenance dose for SCIT ranged from thrice weekly to monthly; for SLIT, it was thrice weekly in all studies. Treatment duration in each study was 1 year. Comparison groups in the studies included SCIT, SLIT, SCIT plus SLIT, and placebo or pharmacotherapy arms. All 3 studies had medium risks of bias.

Clinical Outcomes of SCIT Versus SLIT

For asthma outcomes, Yukselen et al³⁹ favored SCIT and Eifan et al⁴⁰ favored SLIT for improving asthma symptoms and medication use, with moderate magnitudes of effect (Table 1; Supplemental Appendix Table 18). Keles et al⁴¹ found that SCIT, SLIT, and SCIT plus SLIT all led to significant reductions in asthma symptoms, with little difference between them but weakly favoring SCIT over SLIT. Keles et al favored SCIT for decreasing asthma medication use, with a moderate magnitude of effect. For rhinitis outcomes, the studies demonstrated a moderate to strong magnitude of effect in favor of SCIT (Supplemental Appendix Table 19). Two

studies favored SCIT for reducing rhinitis medication use, with moderate and strong magnitudes of effect,^{39,41} and 1 study favored SLIT for reducing total medication use, with a moderate magnitude of effect (Supplemental Appendix Table 20).⁴⁰ Because of the inconsistent direction of change and the few studies available, the strength of evidence is low to support a greater decrease in asthma symptoms, rhinitis symptoms, and medication use with SCIT compared with SLIT.

Safety of SCIT Versus SLIT

Among these 3 studies, local injection site reactions were reported in 3 patients receiving SCIT, and local reactions (oral itching) were reported in 3 patients receiving SLIT (Table 2).^{39–41} No systemic reactions were reported in patients receiving SLIT. Among 37 patients receiving SCIT, 4 experienced systemic reactions, including 1 anaphylaxis event and 3 patients with moderate to severe respiratory symptoms. These studies suggest that SLIT may be safer than SCIT.

DISCUSSION

In this comprehensive, systematic review of SIT for children with asthma and allergic rhinitis, we summarized data from 34 RCTs, including 13 testing SCIT, 18 testing SLIT, and 3 comparing SCIT with SLIT. We found moderate-strength evidence that SCIT improves asthma and rhinitis symptoms and low-strength evidence that SCIT improves conjunctivitis symptoms, lowers asthma medication scores, and improves rhinoconjunctivitis QoL. We found high-strength evidence that SLIT improves asthma symptoms and moderate-strength evidence that SLIT improves rhinitis and conjunctivitis symptoms and decreases medication usage. We found low-strength evidence to support SCIT over SLIT for improving asthma or rhinitis symptoms or medication usage. Local and systemic reactions were common with both regimens.

Anaphylaxis was reported with SCIT in 1 study comparing SCIT with SLIT, and no deaths were reported.

Few previous systematic reviews have evaluated the efficacy of SCIT exclusively in children. Improvements in allergic rhinitis symptoms and medication use, and asthma symptoms and medication use, have been reported with SCIT in previous reviews of combined adult and pediatric populations, without separate pediatric results.^{42,43} Another systematic review reported conflicting results regarding the clinical efficacy of SCIT for allergic rhinoconjunctivitis in children.⁴⁴

Our review of SLIT in children expands on the findings of previous pediatric systematic reviews. Significant reductions in asthma symptoms and medication use with SLIT were similarly reported in previous reviews.^{45,46} For allergic conjunctivitis symptoms, 1 review of 9 studies similarly showed significant reductions in children treated with SLIT,⁴⁷ whereas another review of 7 studies found no significant reductions in conjunctivitis symptoms.⁴⁶ In contrast, several reviews did not find significant reductions in rhinitis or rhinoconjunctivitis symptoms or medication use in children treated with SLIT,^{46,48,49} although decreasing trends were observed in 1 review.⁴⁶

Our systematic review found more evidence to support the use of SLIT than SCIT. This finding may reflect the fact that there are fewer studies evaluating SCIT exclusively in children, and few head-to-head comparisons of SCIT and SLIT. Additional studies directly comparing these 2 modes of delivery or combination regimens may strengthen this evidence base.

Our safety results are consistent with previous studies evaluating SCIT and SLIT, both of which have been shown to be safe in children with allergic rhinitis and mild asthma. Adverse events associated with SCIT include local discomfort,

pain, and serious reactions such as rare fatal and near-fatal reactions.^{50–52} Most adverse events reported with SLIT have been local reactions of the oral mucosa, with few serious systemic reactions. Only a few cases of anaphylaxis have been reported in children receiving SLIT, although none was found in our review.^{52–54}

One important benefit of SIT specific to children may be the potential to modify the response to allergens at an early stage and thus prevent disease progression.^{16,20,21,24,28,31} SIT is currently the only treatment with this potential to modify and prevent progression of disease from allergic rhinitis to asthma.⁵² However, our study found few reports to support SCIT and SLIT for preventing the development of asthma and new sensitizations in children.

Challenges and Study Limitations

Our review involves several challenges and limitations. There was considerable heterogeneity in the study allergens, dosages, dose units, duration of treatment, and in reporting and scoring of outcomes and safety data. This heterogeneity precluded quantitative pooling of the data and made data synthesis challenging. The RCTs that were included in the review varied in their quality. Several studies had moderate or high risk of bias because they did not specify whether allocation schemes were concealed or if the intervention was concealed from the participants and outcome assessors, or did not clarify the role of industry support or sponsors. The majority of SCIT studies were single allergen, and thus the results cannot necessarily be generalized to the use of multiple-allergen regimens, which is common

in the United States. In contrast, the SLIT studies mostly used multiple allergens, and the results are not necessarily generalizable to single-allergen regimens. Safety data were variably reported and only reflect observed reports from RCTs. A more complete evaluation of safety would require inclusion of data from observational studies. Publication bias may also be a concern because we only included studies published in English. Although we requested unpublished data from pharmaceutical companies, we did not receive any information.

Applicability

Our study findings are applicable to children and adolescents with allergic rhinoconjunctivitis or asthma. Our results are relevant to patients making decisions about therapy based on efficacy and safety of SIT, clinicians who provide care for children with asthma and allergic rhinitis, guideline developers making recommendations on SIT in children, and researchers evaluating SIT in children.

CONCLUSIONS

The evidence provides support for the efficacy of both SCIT and SLIT for treatment of allergic rhinitis and asthma in children. The evidence base is stronger for SLIT than for SCIT, which may reflect the fact that there are fewer studies evaluating SCIT exclusively in children and few head-to-head comparisons of SCIT and SLIT. SLIT has been thought to be a favorable alternative to SCIT, especially for children, based on convenience and ease of administration at home without multiple injections,⁵⁵ whereas SCIT requires administration by an experienced provider. These benefits may influence the tolerability

and adherence to treatment, especially in children, but this outcome remains to be seen. Additional studies directly comparing these 2 modes of delivery or combination regimens may strengthen this evidence.

Future pediatric studies should evaluate the real-world effectiveness of SCIT and SLIT, addressing issues of compliance, which are especially relevant in children. In addition, direct comparisons of SCIT versus SLIT should evaluate long-term outcomes such as prevention of asthma and potential for disease modification. Evaluating the differential effects of immunotherapy based on the developmental stage of children and adolescents can help to optimize treatment and identify the optimal dose, frequency, treatment duration, and age for initiating treatment in children.

ACKNOWLEDGMENTS

Peter S. Creticos, MD, Franklin Adkinson, MD, Daniela Vollenweider, MD, and Darcy Ward, MS, assisted in the initial review of the abstracts and publications that were screened and subsequently selected for inclusion. Drs Creticos and Adkinson also helped develop the initial protocol for application of the EPC Methods guide on grading of the included papers, which constituted the work product for this evidence-based review. Dr Creticos was the initial principal investigator. Per the funder's (AHRQ) request, to ensure compliance with established AHRQ conflict of interest policy including perceived conflicts of interest, Drs Creticos and Adkinson were recused from certain review activities (including data extraction, assessment of study quality, and report writing) due to their previous consulting arrangements.

REFERENCES

1. National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary report 2007. *J Allergy Clin Immunol.* 2007;120(suppl 5):S94–S138.

2. Wallace DV, Dykewicz MS, Bernstein DI, et al; Joint Task Force on Practice; American Academy of Allergy Asthma & Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol*. 2008;122(suppl 2):S1–S84
3. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patients in the United States and Europe. *Ann Allergy Asthma Immunol*. 2009;103(6):451–459
4. Altman D, Antes G, Gotzsche P, et al. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.0.2. London, England: The Cochrane Collaboration; 2009
5. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the effective health-care program. *J Clin Epidemiol*. 2010;63(5):513–523
6. Van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. *J Allergy Clin Immunol*. 1990;86(2):141–146
7. Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. *Int Arch Allergy Immunol*. 2009;148(3):251–260
8. Akmanlar N, Altıntaş DU, Güneşer KS, Yilmaz M, Bingöl G. Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy. *Allergol Immunopathol (Madr)*. 2000;28(4):213–218
9. Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. *J Allergy Clin Immunol*. 1999;103(4):609–614
10. Pajno GB, Caminiti L, Crisafulli G, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. *Pediatr Allergy Immunol*. 2011;22(8):803–807
11. Hill DJ, Hosking CS, Shelton MJ, Turner MW. Failure of hyposensitisation in treatment of children with grass-pollen asthma. *Br Med J (Clin Res Ed)*. 1982;284(6312):306–309
12. Altıntaş D, Akmanlar N, Güneşer S, et al. Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children. *Allergol Immunopathol (Madr)*. 1999;27(6):309–317
13. Pifferi M, Baldini G, Marrazzini G, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. *Allergy*. 2002;57(9):785–790
14. Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. *Ann Allergy*. 1986; 57(3):173–179
15. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. *N Engl J Med*. 1997;336(5):324–331
16. Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). *J Allergy Clin Immunol*. 2002;109(2):251–256
17. Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. *J Invest Allergol Clin Immunol*. 1997;7(2):90–97
18. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Gladosporium herbarum preparation. I. Clinical results. *Allergy*. 1986;41(2):131–140
19. Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. *J Allergy Clin Immunol*. 2011;127(2):502–508.e1–6
20. Niggemann B, Jacobsen L, Dreborg S, et al; PAT Investigator Group. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. *Allergy*. 2006;61(7):855–859
21. Jacobsen L, Niggemann B, Dreborg S, et al; the PAT Investigator Group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy*. 2007;62(8):943–948
22. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. *Allergy*. 2000;55(9): 842–849
23. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. *Pediatr Allergy Immunol*. 2006;17(6):408–415
24. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebo-controlled study in Taiwan. *Respir Med*. 2006; 100(8):1374–1383
25. de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. *Pediatr Allergy Immunol*. 2012; 23(2):150–158
26. Tseng SH, Fu LS, Nong BR, Weng JD, Shyur SD. Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial. *Asian Pac J Allergy Immunol*. 2008; 26(2–3):105–112
27. La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 1999;104(2 pt 1):425–432
28. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 2004;114(4):851–857
29. Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. *J Allergy Clin Immunol*. 2007; 119(4):892–898
30. Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. *Allergy*. 2012;67(3):312–320
31. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. *Ann Allergy Asthma Immunol*. 2008;101(2):206–211
32. Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. *Pediatr Allergy Immunol*. 1997;8(1):21–27
33. Bahçeciler NN, Işık U, Barlan IB, Başaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. *Pediatr Pulmonol*. 2001;32(1):49–55
34. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. *Allergol Immunopathol (Madr)*. 1990;18(5):277–284

35. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. *Clin Exp Allergy*. 2003; 33(12):1641–1647
36. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. *Allergy*. 1998;53(7):662–672
37. Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. *Allergy*. 2006; 61(10):1177–1183
38. Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. *Pediatr Allergy Immunol*. 2003;14(3):216–221
39. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. *Int Arch Allergy Immunol*. 2012;157(3):288–298
40. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled study. *Clin Exp Allergy*. 2010;40 (6):922–932.
41. Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. *J Allergy Clin Immunol*. 2011;128(4):808–815.e7
42. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. *Cochrane Database Syst Rev* 2007;(1): CD001936
43. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. *Cochrane Database Syst Rev*. 2010;(8):CD001186
44. Röder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. *Pediatr Allergy Immunol*. 2008;19(3):197–207
45. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest*. 2008;133(3):599–609
46. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. *J Invest Allergol Clin Immunol*. 2005;15(1):9–16
47. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. *Clin Exp Allergy*. 2011;41(9):1263–1272
48. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database Syst Rev*. 2003;(2):CD002893
49. Sopo SM, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. *Arch Dis Child*. 2004; 89(7):620–624
50. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. *J Allergy Clin Immunol*. 2006;117(1):169–175
51. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. *J Allergy Clin Immunol*. 2004;113(6):1129–1136
52. Calderón MA, Larenas D, Kleine-Tebbe J, et al. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy' *Allergy*. 2011;66(10):1345–1359
53. La Rosa M, Lionetti E, Leonardi S, et al. Specific immunotherapy in children: the evidence. *Int J Immunopathol Pharmacol*. 2011;24(suppl 4):69–78
54. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. *Allergy*. 2012;67(3):302–311
55. Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. *Immunol Allergy Clin North Am*. 2011;31(3):561–599

(Continued from first page)

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2013 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: Supported by the Agency for Healthcare Research and Quality (AHRQ) under contract 290-2007-10061-1. The AHRQ program officers and technical experts participated in developing the research questions and reviewed draft manuscripts. The authors are solely responsible for the content and decision to submit for publication. Approval was required from AHRQ for copyright assertion before the manuscript could be submitted for publication. Dr Kim was supported by an AHRQ Comparative Effectiveness Development Training grant (T32HS019488).

Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

Julia M. Kim, Sandra Y. Lin, Catalina Suarez-Cuervo, Yohalakshmi Chelladurai,
Murugappan Ramanathan, Jodi B. Segal and Nkiruka Erekosima

Pediatrics; originally published online May 6, 2013;

DOI: 10.1542/peds.2013-0343

Updated Information & Services	including high resolution figures, can be found at: http://pediatrics.aappublications.org/content/early/2013/04/30/peds.2013-0343
Supplementary Material	Supplementary material can be found at: http://pediatrics.aappublications.org/content/suppl/2013/04/30/peds.2013-0343.DCSupplemental.html
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Allergy & Dermatology http://pediatrics.aappublications.org/cgi/collection/allergy_and_dermatology
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://pediatrics.aappublications.org/site/misc/Permissions.xhtml
Reprints	Information about ordering reprints can be found online: http://pediatrics.aappublications.org/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2013 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



Supplemental Information

Appendix Figure 1

Search strategy used to identify studies for review.

PubMed (6498)

(allergen-specific immunotherapy[tiab] OR allergen immunotherapy[tiab] OR immunotherapy[tiab] OR immunotherapy[mesh] OR immunotherap*[tiab]) AND ((rhinitis[mh] OR rhinitis[tiab] OR hay fever[mh] OR hay fever[tiab] OR rhinoconjunctivitis[tiab] OR conjunctivitis[mh] OR "allergic conjunctivitis"[tiab] OR pollinosis[mh] OR pollinosis[tiab] OR pollenosis[tiab] OR asthma[mh] OR asthma[tiab]) NOT ("occupational diseases"[mh] OR "trachoma"[mh])) NOT (animals[mh] NOT humans[mh])

1	allergen-specific immunotherapy[tiab] OR allergen immunotherapy[tiab] OR immunotherapy[tiab] OR immunotherapy[mesh] OR immunotherap*[tiab]
2	rhinitis[mh] OR rhinitis[tiab] OR hay fever[mh] OR hay fever[tiab] OR rhinoconjunctivitis[tiab] OR conjunctivitis[mh] OR "allergic conjunctivitis"[tiab] OR pollinosis[mh] OR pollinosis[tiab] OR pollenosis[tiab] OR asthma[mh] OR asthma [tiab]
3	"occupational diseases"[mh] OR "trachoma"[mh]
4	2 NOT 3
5	(animals[mh] NOT humans[mh])
6	1 AND 4
7	6 NOT 5

EMBASE (9327)

('immunotherapy'/exp OR desensiti*ation) AND ('rhinitis'/exp OR 'allergic rhinitis'/exp OR 'hay'/exp AND 'fever'/exp OR 'rhinoconjunctivitis'/exp OR 'conjunctivitis'/exp OR 'allergic conjunctivitis'/exp OR 'asthma'/exp) AND [humans]/lim AND [embase]/lim

1	'immunotherapy'/exp OR desensiti*ation
2	'rhinitis'/exp OR 'allergic rhinitis'/exp OR 'hay'/exp AND 'fever'/exp OR 'rhinoconjunctivitis'/exp OR 'conjunctivitis'/exp OR 'allergic conjunctivitis'/exp OR 'asthma'/exp
3	[humans]/lim
4	embase]/lim
5	3 AND 4
6	1 AND 2 AND 5

COCHRANE (840)

Immunotherapy AND (rhinitis OR allergic rhinitis OR rhinoconjunctivitis OR conjunctivitis OR allergic conjunctivitis OR asthma)

LILACS (99)

Immunotherapy AND (rhinitis OR allergic rhinitis OR rhinoconjunctivitis OR conjunctivitis OR allergic conjunctivitis OR asthma)

APPENDIX FIGURE 1

Search strategy used to identify studies for review.

Appendix Figure 2



PRISMA 2009 Checklist – Kim, et al. Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6, Appendix Table 1
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix Fig 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6, Figure 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Appendix Table 1
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7, Appendix Table 3
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8

APPENDIX FIGURE 2
PRISMA checklist.

Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8, 11, 16 Appendix Tables 4, 5, 6
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Appendix Tables 4, 5, 6
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Appendix Tables 4, 5, 6
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Tables 1, 2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9-10, 12-14, 16
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	17-18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	20
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

APPENDIX FIGURE 2

Continued.

APPENDIX TABLE 1 Study Inclusion and Exclusion Criteria

PICO Criteria	Inclusion and Exclusion Criteria
Population and condition of interest	Studies enrolled patients with allergic rhinoconjunctivitis and/or allergic asthma due to airborne allergies Allergic rhinoconjunctivitis must have been confirmed by using skin tests or RAST and asthma must confirmed by using pulmonary lung function tests (FEV₁; methacholine challenge). Studies included adults, the elderly, pregnant women, individuals with severe asthma, monosensitized individuals, minorities, inner-city residents, and rural residents
Interventions	The intervention was SIT alone or with usual care SIT preparation must be available for use in the United States No study of SIT was excluded because of timing or duration of treatment We excluded studies in which dosage units were not specified
Comparisons of interest	We included studies that compared SIT (SCIT or SLIT) versus any of the following: 1. Placebo 2. Any other SIT (any form available in the United States) 3. Pharmacotherapy (positive control) 4. Environmental control 5. Usual care (eg, environmental control, pharmacotherapy) We included studies in which SIT was used alone or in combination with any other treatment and compared with the listed comparators or any other treatment

APPENDIX TABLE 1 Continued

PICO Criteria	Inclusion and Exclusion Criteria
Outcomes	We included studies that reported the following outcomes: Primary outcomes 1. Symptom scores (for rhinitis, conjunctivitis, or asthma) 2. Medication scores 3. Combined symptom and medication scores 4. QoL 5. Safety or harms Secondary outcomes 1. Functional test results (PFT, FEV) 2. Provocational test results (for nasal, conjunctival, or bronchial challenges) 3. Adherence and convenience 4. Long-term effects of SIT (disease modification/prevention of sequelae or new sensitivities)
Timing and setting	We did not impose any limitation on timing or setting
Study design	We included only RCTs

FEV, forced expiratory volume; PFT, pulmonary function testing; RAST, radioallergosorbent test.

APPENDIX TABLE 2 Definitions for Classifications of Magnitude of Effect

Classification of Magnitude of Effect	Definition
Weak	<15% difference in percent change between the SIT group and comparator arm
Moderate	15%–40% difference in percent change between the SIT group and comparator arm
Strong	>40% difference in percent change between the SIT group and comparator arm

APPENDIX TABLE 3 Criteria and Definitions for Grading the Strength of Evidence

Evidence Grade	Criteria	Definition
High	• At least 2 trials having low risk of bias, at least 1 of which has a strong magnitude of effect; and • Overall body of evidence is largely consistent	High confidence that the evidence reflects the true effect, and further research is very unlikely to change our confidence in the estimate of the effect
Moderate	• 1 trial having a low risk of bias with a strong magnitude of effect; or • ≥ 2 trials with medium risk of bias having strong magnitudes of effect; or • 1 trial having low risk of bias with moderate magnitude of effect plus 1 trial having medium risk of bias with strong magnitude of effect; and • Overall body of evidence that is largely consistent	Moderate confidence that the evidence reflects the true effect, and future research may change our confidence in the estimate of the effect and may change the estimate
Low	• There was evidence, but it did not meet the criteria for the above categories	Low confidence that the evidence reflects the true effect, and further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate
Insufficient	• There were no relevant trials.	Evidence is unavailable

APPENDIX TABLE 4 SCIT Affecting Asthma Symptom Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Pifferi et al, 2002 ¹	Dust mite	SCIT pharmacotherapy	800 U	3 y	29	Medium	+	Direct	Strong
Dreborg et al, 1986 ²	<i>Cladospirium</i>	SCIT placebo	100 000 BU (reached after 18 wk)	10 mo	30	Low	+	Direct	Moderate
Kuna et al, 2011 ³	<i>Alternaria</i>	SCIT placebo	1.0 mL (5000 TU/mL) or the highest tolerated dose	3 y	50	Medium	+	Direct	Moderate
Hill et al, 1982 ⁴	Rye	SCIT placebo	75–1000 PNU = 1 PNU of rye pollen	8 mo	20	High	+	Direct	Strong
Adkinson et al, 1997 ⁵	Multiple	SCIT placebo	0.7 mL of concentrate	27 mo	121	Low	–	Direct	Moderate
Cantani et al, 1997 ⁶	Multiple (dust mite, <i>Parietaria</i> , rye)	SCIT pharmacotherapy	500 BU/month	3 y	300	High	+	Direct	Could not determine ^a

PNU, protein nitrogen unit. BU, biologic units; mL, milliliters; TU, treatment units; U, label units.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 5 SCIT Affecting Asthma Medication Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Pifferi et al, 2002 ¹	Dust mite	SCIT pharmacotherapy	800 U	3 y	29	Medium	+	Direct	Strong
Hill et al, 1982 ⁴	Rye	SCIT placebo	75–10 00 PNU = 1 PNU of rye pollen	8 mo	20	High	+	Direct	Moderate
Adkinson et al, 1997 ⁵	Multiple	SCIT placebo	0.7 mL of concentrate	27 mo	121	Low	–	Direct	Weak
Cantani et al, 1997 ⁶	Multiple (dust mite, <i>Parietaria</i> , rye)	SCIT pharmacotherapy	500 BU/month	3 y	300	High	+	Direct	Could not determine ^a

BU, biologic units; mL, milliliters; PNU, protein nitrogen unit; U, label units.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 6 SCIT Affecting Asthma Plus Rhinitis/Rhinoconjunctivitis Medication Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Dreborg et al, 1986 ²	<i>Cladosporium</i>	SCIT placebo	100 000 BU (reached after 18 wk)	10 mo	30	Low	+	Direct	Weak
Kuna et al, 2011 ³	<i>Alternaria</i>	SCIT placebo	1.0 mL (5000 TU/mL) or the highest tolerated dose	3 y	50	Medium	+	Direct	Strong

BU, biologic units; mL, milliliters; TU: Treatment units.

APPENDIX TABLE 7 SCIT Affecting Combined Asthma or Asthma Plus Rhinoconjunctivitis Symptom-Medication Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Altintas et al, 1999 ⁷	Dust mite	SCIT-adsorbed Al; SCIT-adsorbed Ca; SCIT-aqueous; placebo	50 000–100 000 SQ (targeted) 60 000–100 000 SQ (actual) 6–10 IR (10 IR = 1/1000 w/v)	2 y	35	High	+	Direct	Strong
Kuna et al, 2011 ³	<i>Alternaria</i>	SCIT Placebo	1.0 mL (5000 TU/mL) or the highest tolerated dose	3 y	50	Medium	+	Direct	Strong

IR, index of reactivity; mL, milliliters; SQU, standardized quality units; TU, treatment units; w/v, weight to volume.

APPENDIX TABLE 8 SCIT Affecting Rhinitis/Rhinoconjunctivitis Symptom Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Dreborg et al, 1986 ²	<i>Cladosporium</i>	SCIT placebo	100 000 BU (reached after 18 wk)	10 mo	30	Low	+	Direct	Weak
Kuna et al, 2011 ³	<i>Alternaria</i>	SCIT placebo	1.0 mL (5000 TU/mL) or the highest tolerated dose	3 y	50	Medium	+	Direct	Moderate
Möller et al, 2002 ⁸ ; Niggeman et al, 2006 ⁹	Grass/birch	SCIT placebo	100 000 SQU/mL (Alutard SQ® [ALK, Hørsholm,] Denmark)	3 y	205	Medium	+	Direct	Strong

BU, biologic units; mL, milliliters; SQU, standardized quality units; TU, treatment units.

APPENDIX TABLE 9 SCIT Affecting Conjunctivitis Symptom Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Dreborg et al, 1986 ²	<i>Cladosporium</i>	SCIT placebo	100 000 BU (reached after 18 wk)	10 mo	30	Low	+	Direct	Weak
Möller et al, 2002 ⁸ , Niggeman et al, 2006 ⁹	Grass/birch	SCIT placebo	100 000 SQ U/mL (Alutard SQ)	3 y	205	Medium	+	Direct	Could not determine ^a
Kuna et al, 2011 ³	<i>Alternaria</i>	SCIT placebo	1.0 mL (5000 TU/mL) or the highest tolerated dose	3 y	50	Medium	+	Direct	Strong

BU, biologic units; mL, milliliters; SQU, standardized quality units; TU, treatment units.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 10 SCIT Affecting Rhinitis QoL in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Cantani et al, 1997 ⁶	Dust mites, grass, weeds	SCIT pharmacotherapy	500 BU per month	3 y	300	High	+	Direct	Could not determine ^a
Kuna et al, 2011 ³	<i>Alternaria</i>	SCIT placebo	1.0 mL (5000 TU/mL) or the highest tolerated dose	3 y	50	Medium	+	Direct	Strong

BU, biologic units; mL, milliliters; TU, treatment units.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 11 SLIT Affecting Asthma Symptoms in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Pajno et al, 2000 ¹⁰	Dust mite	SLIT placebo	5 drops of 10 BU/mL	2 y	24	Low	Night: + VAS: +	Direct	Night: strong VAS: strong
Lue et al, 2006 ¹¹	Dust mite	SLIT placebo	20 drops of 300 IR/mL	6 mo	20	Medium	+	Direct	Strong
Niu et al, 2006 ¹²	Dust mite	SLIT placebo	20 drops of 300 IR/mL	24 wk	110	Medium	+	Direct	Strong
Hirsch et al, 1997 ¹³	Dust mite	SLIT placebo	7 drops of 11.9 µg/mL = 3.75 µg	1 y	30	Low	+	Direct	Strong
Bahçeciler et al, 2001 ¹⁴	Dust mite	SLIT placebo	20 drops of 100 IR/mL	6 mo	15	Medium	+	Direct	Moderate
Ippoliti et al, 2003 ¹⁵	Dust mite	SLIT placebo	5 drops of 10 BU/mL	6 mo	86	Medium	+	Direct	Strong
Tari et al, 1990 ¹⁶	Dust mite	SLIT placebo	15 drops of 500 STU/mL or 5BU/mL	18 mo	58	Low	+	Direct	Moderate
Pajno et al, 2003 ¹⁷	Parietaria	SLIT placebo	5 drops of 10 BU/mL	13 mo	30	Medium	Sx: + VAS: +	Direct	Sx: Could not determine VAS: could not determine ^a
Valovirta et al, 2006 ¹⁸ , Savolainen et al, 2006 ¹⁹	Tree mix	High dose Low dose Placebo	100 000 SQ-U/mL (per week) 12 000 SQ-U/mL (per week)	5 wk build-up up to 18 mo maintenance	98	Medium	High dose: + Low dose: +	Direct	High dose: strong; Low dose: moderate

BU, biologic units; IR, index of reactivity; Night, nighttime symptom score; SQU, standardized quality units; STU: standardized quality units; Sx: asthma symptom score; VAS: visual analogue scale score.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 12 SLIT Affecting Asthma Plus Rhinitis or Rhinoconjunctivitis Symptoms in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Valovirta et al, 2006 ¹⁸	Tree mix	High dose Low dose	100 000 SQ-U/mL (per week)	5 wk build-up up to 18 mo	98	Medium	High dose: +	Direct	High dose: strong
Savolainen et al, 2006 ¹⁹	Placebo	Placebo	12 000 SQ-U/mL (per week)	18 mo maintenance			Low dose: +		Low dose: moderate

SQ-U, standardized quality units.

APPENDIX TABLE 13 SLIT Affecting Rhinitis or Rhinoconjunctivitis Symptoms in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Röder et al, 2007 ²⁰	Grass mix	SLIT placebo	9500 BU	2 y	204	Low	+	Direct	Weak
Novembre et al, 2004 ²¹	Grass mix	SLIT control	5 drops of 25 BU/mL	3 y	113	High	+	Direct	Could not determine ^a
Tseng et al, 2008 ²²	Dust mite	SLIT placebo	20 drops 300 IR/mL	3 wk induction therapy, 21 wk maintenance	63	Medium	–	Direct	Weak
Hirsch et al, 1997 ¹³	Dust mite	SLIT placebo	7 drops of 11.9 µg/mL = 3.75 µg	1 y	30	Low	+	Direct	Weak
Bahçeciler et al, 2001 ¹⁴	Dust mite	SLIT placebo	20 drops of 100 IR/mL	6 mo	15	Medium	+	Direct	Moderate
Ippoliti et al, 2003 ¹⁵	Dust mite	SLIT placebo	5 drops of 10 BU/mL	6 mo	86	Medium	+	Direct	Strong
Tari et al, 1990 ¹⁶	Dust mite	SLIT placebo	15 drops of 500 STU/mL or 5 BU/mL	18 mo	58	Low	+	Direct	Moderate
de Bot et al, 2012 ²³	Dust mite	SLIT placebo	20 drops = 700 BU	2 y	257	High	+	Direct	Weak
La Rosa et al, 1999 ²⁴	<i>Parietaria</i>	SLIT placebo	20 drops of 300 IR/mL	2 y	41	Low	+	Direct	Could not determine ^a
Pajno et al, 2003 ¹⁷	<i>Parietaria</i>	SLIT placebo	5 drops of 10 BU/mL	13 mo	30	Medium	+	Direct	Could not determine ^a
Vourdas et al, 1998 ²⁵	Olive	SLIT placebo	20 drops of 300 IR/mL	Seasonal (6 mo each year) for 2 y	70	Medium	+	Direct	Strong
Valovirta et al, 2006 ¹⁸ , Savolainen et al, 2006 ¹⁹	Tree mix	High dose Low dose Placebo	100 000 SQ-U/mL (per week) 12 000 SQ-U/mL (per week)	5 wk build-up up to 18 mo 18 mo maintenance	98	Medium	High dose: + Low dose: +	Direct	High dose: strong Low dose: moderate

BU, biologic units; IR, index of reactivity; SQU, standardized quality units; STU, standard treatment units.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 14 SLIT Affecting Conjunctivitis Symptoms in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Tari et al, 1990 ¹⁶	Dust mite	SLIT placebo	15 drops of 500 STU/mL or 5BU/mL	18 mo	58	Low	+	Direct	Weak
de Bot et al, 2012 ²³	Dust mite	SLIT placebo	20 drops = 700 BU	2 y	257	High	+	Direct	Could not determine ^a
Yourdas et al, 1998 ²⁵	Olive	SLIT Placebo	20 drops of 300 IR/mL	Seasonal (6 mo each year) for 2 y	70	Medium	+	Direct	Strong
Valovirta et al, 2006 ¹⁸	Tree mix	High dose Low dose Placebo	100 000 SQ-U/mL (per week)	5-wk build-up up to 18-mo maintenance	98	Medium	High dose: + Low dose: +	Direct	High dose: Strong Low dose: Moderate
Savolainen et al, 2006 ¹⁹	<i>Parietaria</i>	SLIT placebo	12 000 SQ-U/mL (per week)	13 mo	30	Low	NR	Direct	Could not determine ^a
Pajno et al, 2003 ¹⁷			5 drops of 10 BU/mL						

BU, biologic units; IR, Index of Reactivity; NR, not reported; SQ-U, standardized quality units; STU, standard treatment units.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 15 SLIT Affecting Medication Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Pajno et al, 2000 ¹⁰	Dust mite	SLIT placebo	5 drops of 10 BU/mL	2 y	27	Low	+	Direct	Strong
Lue et al, 2006 ¹¹	Dust mite	SLIT placebo	20 drops of 300 IR/mL	6 mo	20	Medium	+	Direct	Moderate
Niu et al, 2006 ¹²	Dust mite	SLIT placebo	20 drops of 300 IR/mL	24 wk	110	High	AH: + BA: + ICS: + OC: +	Direct	AH: strong BA: strong ICS: weak OC: strong
Tseng et al, 2008 ²²	Dust mite	SLIT placebo	20 drops 300 IR/mL	3-wk induction therapy, 21-wk maintenance	63	Medium	AH: + BA: –	Direct	AH: moderate BA: moderate
Hirsch et al, 1997 ¹³	Dust mite	SLIT placebo	7 drops of 11.9 µg/mL = 3.75 µg	1 y	30	Low	AH/INS: – BA/Th: +	Direct	Could not determine ^a
de Bot et al, 2012 ²³	Dust mite	SLIT placebo	20 drops = 700 BU	2 y	257	High	+	Direct	Could not determine ^a
Röder et al, 2007 ⁴⁰	Grass mix	SLIT placebo	9500 BU	2 y	204	Low	–	Direct	Could not determine ^a
Novembre et al, 2004 ²¹	Grass mix	SLIT control	20 drops 100 IR/mL	6 mo	113	High	+	Direct	Could not determine ^a
La Rosa et al, 1998 ²⁴	<i>Parietaria</i>	SLIT placebo	20 drops of 300 IR/mL	2 y	41	Low	Could not determine ^a	Direct	Could not determine ^a
Leonardi et al, 2009 ²⁶									
Pajno et al, 2003 ¹⁷	<i>Parietaria</i>	SLIT placebo	5 drops of 10 BU/mL	13 mo	30	Low	+	Direct	Could not determine ^a
Yourdas et al, 1998 ²⁵	Olive	SLIT placebo	20 drops of 300 IR/mL	Seasonal (6 mo each year) for 2 y	70	Medium	OC: + NR for other medications	Direct	Could not determine ^a
Valovirta et al, 2006 ¹⁸	Tree mix	High-dose Low-dose Placebo	100 000 SQ-U/mL (per week)	5-wk build-up up to 18-mo maintenance	98	Medium	High dose: + Low dose: +	Direct	High dose: Moderate Low dose: Weak
Savolainen et al, 2006 ¹⁹									
Bahçeciler et al, 2001 ¹⁴	Grass mix and olive	SLIT placebo	20 drops of 100 IR/mL	6 mo	15	Medium	BA: + ICS: + INS: +	Direct	BA: Moderate ICS: Strong INS: Strong

AH, antihistamine; BA, beta agonist; BU, biologic units; ICS, inhaled corticosteroid; INS, intranasal steroid; IR, index of reactivity; NR, not reported; OC, oral corticosteroids; SQ-U, standardized quality units; Th, theophylline.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.

APPENDIX TABLE 16 SLIT Affecting Combined Symptom Plus Medication Scores in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
Marogna et al, 2008 ²⁷	Dust mite, birch, grass mix, <i>Parietaria</i>	SLIT control	5 drops 10,000 RU/mL	3 y	216	Medium	+	Direct	Strong
Novembre et al, 2004 ²¹	Grass mix	SLIT control	20 drops 100 IR/mL	6 mo	113	High	+	Direct	Could not determine ^a

IR, index of reactivity; RU, radioallergosorbent test units.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.**APPENDIX TABLE 17** SLIT Affecting QoL in Children and Adolescents

Study	Measurement Tool	Allergen/Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Direction of Change	Directness	Magnitude of Effect
de Bot et al, 2012 ²⁵	Pediatric RQLQ ¹ Adolescent RQLQ ¹	Dust mite/SLIT placebo	20 drops = 700 BU	2 y	257	High	–	Direct	Could not determine ^a Could not determine ^a
Röder et al, 2007 ²⁰	Pediatric RQLQ ¹ Adolescent RQLQ ¹	Grass mix/SLIT placebo	9500 BU	2 y	204	Low	–	Direct	Could not determine ^a Could not determine ^a

BU, biologic units; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire.

^a Could not determine, because there was not enough data provided in the article to calculate the magnitude of effect.**APPENDIX TABLE 18** SLIT Versus SCIT Affecting Asthma Symptoms in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Treatment favored	Directness	Magnitude of Effect
Yukselen et al, 2012 ²⁸	Dust mite	SLIT + placebo injections SCIT + placebo drops	0.2–0.8 mL of 5000 TU/mL 28 drops of 1000 TU/mL	1 y	31	Medium	SCIT	Direct	Moderate
Erfan et al, 2010 ²⁹	Dust mite	Placebo injections + drops SLIT SCIT	5 drops STU (1000 STU/mL) 100 000 SQ U/mL, 1 cm ³	1 y	48	Medium	SLIT	Direct	Moderate
Keles et al, 2011 ³⁰	Dust mite	Pharmacotherapy SLIT SCIT SLIT + SCIT Pharmacotherapy	44.12 µg of Der p1 + 62.1 µg of Df1 52.8 µg of Der p1 + 52.8 µg of Df1 43.2 µg of Der p1 + 43.2 µg of Df1	1 y	56	Medium	SCIT	Direct	Weak

SQU, standardized quality units; STU, standard treatment units; TU, treatment units.

APPENDIX TABLE 19 SLIT Versus SCIT Affecting Rhinitis/Rhinoconjunctivitis Symptoms in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Treatment Favored	Directness	Magnitude of Effect
Yukselen et al, 2012 ²⁸	Dust mite	SLIT + placebo injections SCIT + placebo drops	0.2–0.8 mL of 5000 TU/mL 28 drops of 1000 TU/mL	1 y	31	Medium	SCIT	Direct	Moderate
Eifan et al, 2010 ²⁹	Dust mite	Placebo injections + drops SLIT SCIT	5 drops STU (1000 STU/mL)	1 y	48	Medium	SLIT	Direct	Strong
Keles et al, 2011 ³⁰	Dust mite	Pharmacotherapy SLIT SCIT SLIT + SCIT Pharmacotherapy	100 000 SQ U/mL, 1cm ³ 44.12 µg of Der p1 + 62.1 µg of Df1 52.8 µg of Der p1 + 52.8 µg of Df1 43.2 µg of Der p1 + 43.2 µg of Df1	1 y	56	Medium	SCIT	Direct	Weak

SQU, standardized quality units; STU, standard treatment units; TU, treatment units.

APPENDIX TABLE 20 SLIT Versus SCIT Affecting Medication Use in Children and Adolescents

Study	Allergen	Comparator	Maintenance Dose	Duration of Treatment	No. of Participants	Risk of Bias	Treatment favored	Directness	Magnitude of Effect
Yukselen et al, 2012 ²⁸	Dust mite	SLIT + placebo injections SCIT + placebo drops	0.2–0.8 mL of 5000 TU/mL 28 drops of 1000 TU/mL	1 y	31	Medium	SCIT	Direct	Moderate
Eifan et al, 2010 ²⁹	Dust mite	Placebo injections + drops SLIT SCIT	5 drops STU (1000 STU/mL)	1 y	48	Medium	SLIT	Direct	Moderate
Keles et al, 2011 ³⁰	Dust mite	Pharmacotherapy SLIT SCIT SLIT + SCIT Pharmacotherapy	100 000 SQ U/mL, 1cm ³ 44.12 µg of Der p1 + 62.1 µg of Df1 52.8 µg of Der p1 + 52.8 µg of Df1 43.2 µg of Der p1 + 43.2 µg of Df1	1 y	56	Medium	SCIT	Direct	Strong

SQU, standardized quality units; STU, standard treatment units; TU, treatment units.

SUPPLEMENTAL REFERENCES

- Pifferi M, Baldini G, Marrazzini G, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. *Allergy*. 2002;57(9):785–790
- Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. *Allergy*. 1986;41(2):131–140
- Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. *J Allergy Clin Immunol*. 2011;127(2):502–508.e1–6
- Hill DJ, Hosking CS, Shelton MJ, Turner MW. Failure of hyposensitisation in treatment of children with grass-pollen asthma. *Br Med J (Clin Res Ed)*. 1982;284(6312):306–309
- Adkinson NF, Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. *N Engl J Med*. 1997;336(5):324–331
- Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. *J Investig Allergol Clin Immunol*. 1997;7(2):90–97
- Altıntaş D, Akmanlar N, Güneşer S, et al. Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children. *Allergol Immunopathol (Madr)*. 1999;27(6):309–317
- Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). *J Allergy Clin Immunol*. 2002;109(2):251–256
- Niggemann B, Jacobsen L, Dreborg S, et al; PAT Investigator Group. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. *Allergy*. 2006;61(7):855–859
- Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. *Allergy*. 2000;55(9):842–849
- Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. *Pediatr Allergy Immunol*. 2006;17(6):408–415
- Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebo-controlled study in Taiwan. *Respir Med*. 2006;100(8):1374–1383
- Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. *Pediatr Allergy Immunol*. 1997;8(1):21–27
- Bahçeciler NN, Işık U, Barlan IB, Başaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. *Pediatr Pulmonol*. 2001;32(1):49–55
- Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. *Pediatr Allergy Immunol*. 2003;14(3):216–221
- Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. *Allergol Immunopathol (Madr)*. 1990;18(5):277–284
- Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. *Clin Exp Allergy*. 2003;33(12):1641–1647
- Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. *Allergy*. 2006;61(10):1177–1183
- Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. *Allergy*. 2006;61(10):1184–1190
- Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. *J Allergy Clin Immunol*. 2007;119(4):892–898
- Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 2004;114(4):851–857
- Tseng SH, Fu LS, Nong BR, Weng JD, Shyur SD. Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial. *Asian Pac J Allergy Immunol*. 2008;26(2–3):105–112
- de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. *Pediatr Allergy Immunol*. 2012;23(2):150–158
- La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 1999;104(2 pt 1):425–432
- Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. *Allergy*. 1998;53(7):662–672
- Leonardi S, Spicuzza L, La Rosa M. High-dose sublingual immunotherapy in children at 8-year follow-up. *Ann Allergy Asthma Immunol*. 2009;102(3):259–260
- Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. *Ann Allergy Asthma Immunol*. 2008;101(2):206–211
- Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. *Int Arch Allergy Immunol*. 2012;157(3):288–298
- Eifan A, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled study. *Clin Exp Allergy*. 2010;40(6):922–932
- Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. *J Allergy Clin Immunol*. 2011;128(4):808–815.e7

Pediatrics eLetters

Clarification of definitions of single and multiple allergen immunotherapy

[Julia M. Kim](#), Comparative Effectiveness Research and General Academic Pediatrics Fellow
Sandra Y. Lin, Catalina Suarez-Cuervo, Yohalakshmi Chelladurai, Murugappan Ramanathan, Jodi B. Segal, and Nkiruka Erekosima
Johns Hopkins University

We would like to clarify our definitions of single and multiple allergen immunotherapy. In this review, multiple allergen immunotherapy was defined as the use of extracts containing more than one allergen species, including cross-reacting allergens. Single allergen immunotherapy was defined as the use of a single allergen species, and not by a class of allergens. For example, a study using grass mix allergens (or tree mix, or 2 dust mite species) was considered to be a multiple allergen study. With this definition, the majority of SLIT studies were reported as using multiple allergens (60%), with a limitation being that the results may not be generalizable to single allergen regimens.

We understand that allergists may apply different definitions of single and multiple allergen immunotherapy to our findings. Multiple allergen immunotherapy can be defined as the use of extracts containing more than one allergen class, whereas single allergen immunotherapy can refer to the use of closely related allergens within the same class. For example, a study using a grass mix allergen (or tree mix, or 2 dust mite species) could be considered a single allergen study, whereas a multiple allergen study could use different classes of allergens, such as tree and grass. If this definition is applied, then 17 of the 18 SLIT studies in our review would be considered single allergen studies (94%), and a limitation of the study would be that the SLIT results may not be generalizable to multiple allergen regimens. This definition would not change our results for SCIT studies, with the majority remaining single allergen studies.

Conflict of Interest:

None declared

Published May 22, 2013